Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression

Frontiers in Immunology

Volumn 9, Issue MAR, 2018, Pages

  Fleming, Viktor ^a,b   Hu, Xiaoying ^a,b   Weber, Rebekka ^a,b   Nagibin, Vasyl ^a,b   Groth, Christopher ^a,b   Altevogt, Peter ^a,b   Utikal, Jochen ^a,b   Umansky, Viktor ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer immunotherapy; Immunosuppression; Myeloid derived suppressor cells; Therapeutic targeting; Tumor microenvironment

Indexed keywords

ARGINASE 1; BUSULFAN; CAPECITABINE; CD14 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CISPLATIN; FAS LIGAND; FIBROBLAST GROWTH FACTOR 2; FLUDARABINE; GELATINASE B; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; IPILIMUMAB; KYNURENINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; METHOTREXATE; NIVOLUMAB; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PROSTAGLANDIN E2; RANITIDINE; RANTES; TADALAFIL; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER STAGING; CD4+ T LYMPHOCYTE; CELL CYCLE ARREST; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DOWN REGULATION; EXOSOME; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LEWIS CARCINOMA; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; MEMBRANE MICROPARTICLE; METASTASIS; MYELODYSPLASTIC SYNDROME; MYELOID-DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TLR SIGNALING; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE;

EID: 85048129720     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.00398     Document Type: Review

References (111)

1. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev (2008) 18:11-8. doi:10.1016/j.gde.2007.12.007
2. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother (2011) 60:319-26. doi:10.1007/s00262-010-0968-0
3. Umansky V, Sevko A. Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron (2013) 6:169-77. doi:10.1007/s12307-012-0126-7
4. Hansen GL, Gaudernack G, Brunsvig PF, Cvancarova M, Kyte JA. Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. Cancer Immunol Immunother (2015) 64:1609-21. doi:10.1007/s00262-015-1766-5
5. Limagne E, Euvrard R, Thibaudin M, Rébé C, Derangere V, Chevriaux A, et al. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predict the efficacy of a FOLFOX-bevacizumab drug treatment regimen. Cancer Res (2016) 76:5241-52. doi:10.1158/0008-5472.CAN-15-3164
6. Gabrilovich D, Nagaraj S. Myeloid-derived-suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 9:162-74. doi:10.1038/nri2506
7. Gabrilovich D. Myeloid-derived suppressor cells. Cancer Immunol Res (2017) 5:3-8. doi:10.1158/2326-6066
8. Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res (2015) 128:95-139. doi:10.1016/bs.acr.2015.04.002
9. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol (2016) 37:208-20. doi:10.1016/j.it.2016.01.004
10. Meirow Y, Kanterman J, Baniyash M. Paving the road to tumor development and spreading: myeloid-derived suppressor cells are ruling the fate. Front Immunol (2015) 6:523. doi:10.3389/fimmu.2015.00523
11. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 182:4499-506. doi:10.4049/jimmunol.0802740
12. Ray A, Chakraborty K, Ray P. Immunosuppressive MDSCs induced by TLR signaling during infection and role in resolution of inflammation. Front Cell Infect Microbiol (2013) 3:52. doi:10.3389/fcimb.2013.00052
13. Loftus TJ, Mohr AM, Moldawer LL. Dysregulated myelopoiesis and hematopoietic function following acute physiologic insult. Curr Opin Hematol (2018) 25(1):37-43. doi:10.1097/MOH.0000000000000395
14. Ueha S, Shand FH, Matsushima K. Myeloid cell population dynamics in healthy and tumor-bearing mice. Int Immunopharmacol (2011) 11:783-8. doi:10.1016/j.intimp.2011.03.003
15. Yin B, Ma G, Yen CY, Zhou Z, Wang GX, Divino CM, et al. Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol (2010) 185:5828-34. doi:10.4049/jimmunol.0903636
16. Gabrilovich D, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12:253-68. doi:10.1038/nri3175
17. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Mandruzzato S, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun (2016) 7:12150. doi:10.1038/ncomms12150
18. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci (2014) 1319:47-65. doi:10.1111/nyas.12469
19. Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol (2016) 1(2):aaf8943. doi:10.1126/sciimmunol.aaf8943
20. Umansky V, Blattner C, Gebhardt C, Utikal J. The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines (Basel) (2016) 4:36. doi:10.3390/vaccines4040036
21. Wesolowski R, Markowitz J, Carson WE. Myeloid derived suppressor cells-a new therapeutic target in the treatment of cancer. J Immunother Cancer (2013) 1:10. doi:10.1186/2051-1426-1-10
22. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest (2015) 125:3356-64. doi:10.1172/JCI80005
23. Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest (2015) 125:3365-76. doi:10.1172/JCI80006
24. Isola AL, Chen S. Exosomes: the messengers of health and disease. Curr Neuropharmacol (2017) 15:157-65. doi:10.2174/1570159X14666160825160421
25. Ruivo CF, Adem B, Silva M, Melo SA. The biology of cancer exosomes: insights and new perspectives. Cancer Res (2017) 77(23):6480-8. doi:10.1158/0008-5472.CAN-17-0994
26. Ridder K, Sevko A, Heide J, Rupp AK, Macas J, Starmann J, et al. Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. Oncoimmunology (2015) 4:e1008371. doi:10.1080/2162402X.2015.1008371
27. Filipazzi P, Bürdek M, Villa A, Rivoltini L, Huber V. Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol (2012) 22:342-9. doi:10.1016/j.semcancer.2012.02.005
28. Bretz NP, Ridinger J, Rupp AK, Rimbach K, Keller S, Rupp C, et al. Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via toll-like receptor signaling. J Biol Chem (2013) 288:36691-702. doi:10.1074/jbc. M113.512806
29. Chow A, Zhou W, Liu L, Fong MY, Champer J, Van Haute D, et al. Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-κB. Sci Rep (2014) 4:5750. doi:10.1038/srep05750
30. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, et al. Membrane associated Hsp72 from tumor derived exosomes mediates STAT3 dependent immunosuppressive function of mouse and human myeloid derived suppressor cells. J Clin Invest (2010) 120:457-71. doi:10.1172/JCI40483
31. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells. Nat Med (2012) 18:883-91. doi:10.1038/nm.2753
32. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res (2008) 68:2561-3. doi:10.1158/0008-5472.CAN-07-6229
33. Umansky V, Blattner C, Fleming V, Hu X, Gebhardt C, Altevogt P, et al. Myeloid-derived suppressor cells and tumor escape from immune surveillance. Semin Immunopathol (2017) 39:295-305. doi:10.1007/s00281-016-0597-6
34. Bronte V, Serafini P, De Stanto C, Marigo I, Tosello V, Mazzoni A, et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol (2003) 170:270-8. doi:10.4049/jimmunol.170.1.270
35. Bronte V, Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol (2005) 5:641-54. doi:10.1038/nri1668
36. Rodriguez PC, Quiceno DG, Ochoa AC. l-arginine availability regulates T-lymphocyte cell-cycle progression. Blood (2007) 109:1568-74. doi:10.1182/blood-2006-06-031856
37. Baniyash M. TCR ?-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol (2004) 4:675-87. doi:10.1038/nri1434
38. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 168:689-95. doi:10.4049/jimmunol.168.2.689
39. Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res (2012) 72:5435-40. doi:10.1158/0008-5472.CAN-12-0569
40. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity (2005) 22:633-42. doi:10.1016/j.immuni.2005.03.013
41. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med (2002) 196:459-68. doi:10.1084/jem.20020121
42. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol (2010) 185:3190-8. doi:10.4049/jimmunol.0903670
43. Fallarino F, Grohmann U, Vacca C, Orabona C, Spreca A, Fioretti MC, et al. T cell apoptosis by kynurenines. Adv Exp Med Biol (2003) 527:183-90. doi:10.1007/978-1-4615-0135-0_21
44. Della CM, Carlomagno S, Frumento G, Balsamo M, Cantoni C, Conte R, et al. The tryptophan catabolite l-kynurenine inhibits the surface expression of NKp46-and NKG2D-activating receptors and regulates NK-cell function. Blood (2006) 108:4118-25. doi:10.1182/blood-2006-03-006700
45. Hardy LL, Wick DA, Webb JR. Conversion of tyrosine to the inflammation-associated analog 3'-nitrotyrosine at either TCR-or MHC-contact positions can profoundly affect recognition of the MHC class i-restricted epitope of lymphocytic choriomeningitis virus glycoprotein 33 by CD8 T cells. J Immunol (2008) 180:5956-62. doi:10.4049/jimmunol.180.9.5956
46. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1-and M2-type characteristics. J Leukoc Biol (2008) 83:1136-44. doi:10.1189/jlb.090761
47. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol (2007) 179:977-83. doi:10.4049/jimmunol.179.2.977
48. Berger KN, Pu JJ. PD-1 pathway and its clinical application: a 20 year journey after discovery of the complete human PD-1 gene. Gene (2017) 638:20-5. doi:10.1016/j.gene.2017.09.050
49. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1a, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med (2014) 211:781-90. doi:10.1084/jem.20131916
50. Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood (2011) 117:5381-90. doi:10.1182/blood-2010-11-321752
51. Safarzadeh E, Orangi M, Mohammadi H, Babai F, Baradaran B. Myeloid-derived suppressor cells: important contributors to tumor progression and metastasis. J Cell Physiol (2018) 233(4):3024-36. doi:10.1002/jcp.26075
52. Baniyash M. Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy. Cancer Immunol Immunother (2016) 65:857-67. doi:10.1007/s00262-016-1849-y
53. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol (2011) 21:139-46. doi:10.1016/j.semcancer.2011.01.002
54. Kitamura T, Qian B, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol (2015) 15:73-86. doi:10.1038/nri3789
55. Sceneay J, Parker BS, Smyth MJ, Möller A. Hypoxia-driven immunosuppression contributes to the pre-metastatic niche. Oncoimmunology (2013) 2:e22355. doi:10.4161/onci.22355
56. Jacob A, Prekeris R. The regulation of MMP targeting to invadopodia during cancer metastasis. Front Cell Dev Biol (2015) 3:4. doi:10.3389/fcell.2015.00004
57. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 285:1182-6. doi:10.1056/NEJM197111182852108
58. Shen P, Wang A, He M, Wang Q, Zheng S. Increased circulating Lin-/low CD33+ HLA-DR-myeloid-derived suppressor cells in hepatocellular carcinoma patients. Hepatol Res (2014) 44:639-50. doi:10.1111/hepr.12167
59. Pan W, Sun Q, Wang Y, Wang J, Cao S, Ren X. Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment. Tumor Biol (2015) 36:3159-69. doi:10.1007/s13277-015-3363-9
60. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 166:678-89. doi:10.4049/jimmunol.166.1.678
61. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother (2011) 60:1419-30. doi:10.1007/s00262-011-1028-0
62. Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P, et al. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer (2012) 130:1109-19. doi:10.1002/ijc.26123
63. Jiang H, Gebhardt C, Umansky L, Beckhove P, Schulze TJ, Utikal J, et al. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer (2015) 136:2352-60. doi:10.1002/ijc.29297
64. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2009) 58:49-59. doi:10.1007/s00262-008-0523-4
65. Pico de Coaña Y, Poschke I, Gentilcore G, Mao Y, Nyström M, Hansson J, et al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their arginase1 production. Cancer Immunol Res (2013) 1:158-62. doi:10.1158/2326-6066.CIR-13-0016
66. Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res (2015) 21:5453-9. doi:10.1158/1078-0432.CCR-15-0676
67. Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, et al. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer (2014) 2:31. doi:10.1186/s40425-014-0031-3
68. Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A, et al. Clinical significance of circulating CD33+CD11b+HLA-DR-myeloid cells in patients with stage iv melanoma treated with ipilimumab. Clin Cancer Res (2016) 22:5661-72. doi:10.1158/1078-0432.CCR-15-3104
69. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 203:2691-702. doi:10.1084/jem.20061104
70. Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A (2011) 108:17111-6. doi:10.1073/pnas.1108121108
71. Lin S, Wang J, Wang L, Wen J, Guo Y, Qiao W, et al. Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC. Am J Cancer Res (2017) 7:41-52
72. Califano J, Khan Z, Noonan K, Rudraraju L, Zhang Z, Wang H, et al. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res (2015) 21:30-8. doi:10.1158/1078-0432.CCR-14-1716
73. Weed DT, Vella JL, Reis IM, De la Fuente AC, Gomez C, Sargi Z, et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res (2015) 21:39-48. doi:10.1158/1078-0432.CCR-14-1711
74. Hassel JC, Jiang H, Bender C, Winkler J, Sevko A, Shevchenko I, et al. Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic melanoma (TaMe). Oncoimmunology (2017) 6:e1326440. doi:10.1080/2162402X.2017.1326440
75. Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S, et al. Entinostat neutralizes myeloid derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. Clin Cancer Res (2017) 23:5187-201. doi:10.1158/1078-0432.CCR-17-0741
76. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A (2014) 111:11774-9. doi:10.1073/pnas.1410626111
77. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 9:798-809. doi:10.1038/nrc2734
78. Kortylewski M, Moreira D. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother (2017) 66:979-88. doi:10.1007/s00262-017-1966-2
79. Spinetti T, Spagnuolo L, Mottas I, Secondini C, Treinies M, Rüegg C, et al. TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function. Oncoimmunology (2016) 5:e1230578. doi:10.1080/2162402X.2016.1230578
80. Zhang Q, Hossain DM, Duttagupta P, Moreira D, Zhao X, Won H, et al. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood (2016) 127:1687-700. doi:10.1182/blood-2015-08-665604
81. Hossain F, Al-Khami AA, Wyczechowska D, Hernandez C, Zheng L, Reiss K, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res (2015) 3:1236-47. doi:10.1158/2326-6066.CIR-15-0036
82. Al-Khami AA, Rodriguez PC, Ochoa AC. Energy metabolic pathways control the fate and function of myeloid immune cells. J Leukoc Biol (2017) 102:369-80. doi:10.1189/jlb.1VMR1216-535R
83. Al-Khami AA, Zheng L, Del Valle L, Hossain F, Wyczechowska D, Zabaleta J, et al. Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. Oncoimmunology (2017) 30:e1344804. doi:10.1080/2162402X.2017.1344804
84. Homey B, Müller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol (2002) 2:175-84. doi:10.1038/nri748
85. Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, et al. Monocytic CCR2+ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res (2012) 72:876-86. doi:10.1158/0008-5472.CAN-11-1792
86. Izhak L, Wildbaum G, Weinberg U, Shaked Y, Alami J, Dumont D, et al. Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner. J Immunol (2010) 184:1092-101. doi:10.4049/jimmunol.0902725
87. Blattner C, Fleming V, Weber R, Himmelhan BS, Altevogt P, Gebhardt C, et al. CCR5+ myeloid-derived suppressor cells are enriched and activated in melanoma lesions. Cancer Res (2018) 78:157-67. doi:10.1158/0008-5472.CAN-17-0348
88. Izhak L, Wildbaum G, Zohar Y, Anunu R, Klapper L, Elkeles A, et al. A novel recombinant fusion protein encoding a 20-amino acid residue of the third extracellular (E3) domain of CCR2 neutralizes the biological activity of CCL2. J Immunol (2009) 183:732-9. doi:10.4049/jimmunol.0802746
89. Combadiere C, Ahuja SK, Tiffany HL, Murphy PM. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J Leukoc Biol (1996) 60:147-52. doi:10.1002/jlb.60.1.147
90. Balistreri CR, Carruba G, Calabrò M, Campisi I, Di Carlo D, Lio D, et al. CCR5 proinflammatory allele in prostate cancer risk: a pilot study in patients and centenarians from Sicily. Ann N Y Acad Sci (2009) 1155:289-92. doi:10.1111/j.1749-6632.2008.03691.x
91. Umansky V, Blattner C, Gebhardt C, Utikal J. CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. Cancer Immunol Immunother (2017) 66:1015-23. doi:10.1007/s00262-017-1988-9
92. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res (2003) 63:8360-5
93. Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol (2009) 182:1746-55. doi:10.4049/jimmunol.182.3.1746
94. Velasco-Velázquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res (2012) 72:3839-50. doi:10.1158/0008-5472.CAN-11-3917
95. Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res (2007) 67:11021-8. doi:10.1158/0008-5472.CAN-07-2593
96. Li Y, Wongsiriroj N, Blaner WS. The multifaceted nature of retinoid transport and metabolism. Hepatobiliary Surg Nutr (2014) 3:126-39. doi:10.3978/j.issn.2304-3881.2014.05.04
97. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res (2006) 66:9299-307. doi:10.1158/0008-5472.CAN-06-1690
98. Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother (2013) 6:909-18. doi:10.1007/s00262-013-1396-8
99. Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, et al. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res (2011) 13(3):R66. doi:10.1186/bcr2903
100. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 15:2148-57. doi:10.1158/1078-0432.CCR-08-1332
101. Nayak D, Roth TL, Mcgavern DB. Myeloid-derived suppressor cells as an immune parameter in patients with concurrent sunitinib and stereotactic body radiotherapy. Clin Cancer Res (2010) 21:4073-85. doi:10.1158/1078-0432.CCR-14-2742
102. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res (2010) 70:3052-61. doi:10.1158/0008-5472.CAN-09-3690
103. Eriksson E, Wenthe J, Irenaeus S, Loskog A, Ullenhag G. Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. J Transl Med (2016) 14:282. doi:10.1186/s12967-016-1037-z
104. Kanterman J, Sade-Feldman M, Biton M, Ish-Shalom E, Lasry A, Goldshtein A, et al. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res (2014) 74:6022-35. doi:10.1158/0008-5472.CAN-14-0657
105. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res (2010) 16:4583-94. doi:10.1158/1078-0432.CCR-10-0733
106. Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res (2014) 74:104-18. doi:10.1158/0008-5472.CAN-13-1545
107. Sevko A, Michels T, Vrohlings M, Umansky L, Beckhove P, Kato M, et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol (2013) 190:2464-71. doi:10.4049/jimmunol.1202781
108. Michels T, Shurin GV, Naiditch H, Sevko A, Umansky V, Shurin MR. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J Immunotoxicol (2012) 9:292-300. doi:10.3109/1547691X.2011.642418
109. Danishmalik SN, Sin JI. Therapeutic tumor control of HER2 DNA vaccines is achieved by an alteration of tumor cells and tumor microenvironment by gemcitabine and anti-Gr-1 Ab treatment in a HER2-expressing tumor model. DNA Cell Biol (2017) 6:801-11. doi:10.1089/dna.2017.3810
110. Draghiciu O, Lubbers J, Nijman HW, Daemen T. Myeloid derived suppressor cells-an overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology (2015) 4:e954829. doi:10.4161/21624011.2014.954829
111. Tobin RP, Davis D, Jordan KR, McCarter MD. The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients. J Leukoc Biol (2017) 102:381-91. doi:10.1189/jlb.5VMR1016-449R